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Background Since 2002, development assistance for health has substantially increased,
especially investments for HIV, tuberculosis (TB) and malaria control. We
undertook a systematic review to assess and synthesize the existing evidence in
the scientific literature on the health impacts of these investments.
Methods
and findings We systematically searched databases for peer-reviewed and grey literature,
using tailored search strategies. We screened studies for study design and
relevance, using predefined inclusion criteria, and selected those that enabled us
to link health outcomes or impact to increased external funding. For all included
studies, we recorded dataset and study characteristics, health outcomes and
impacts. We analysed the data using a causal-chain framework to develop a
narrative summary of the published evidence.
Thirteen articles, representing 11 individual studies set in Africa and Asia
reporting impacts on HIV, tuberculosis and malaria, met the inclusion criteria.
Only two of these studies documented the entire causal-chain spanning from
funding to programme scale-up, to outputs, outcomes and impacts. Nonetheless,
overall we find a positive correlation between consecutive steps in the causal
chain, suggesting that external funds for HIV, tuberculosis and malaria
programmes contributed to improved health outcomes and impact.
Conclusions Despite the large number of supported programmes worldwide and despite an
abundance of published studies on HIV, TB and malaria control, we identified
very few eligible studies that adequately demonstrated the full process by which
external funding has been translated to health impact. Most of these studies did
not move beyond demonstrating statistical association, as opposed to contribu-
tion or causation. We thus recommend that funding organizations and
researchers increase the emphasis on ensuring data capture along the causal
pathway to demonstrate effect and contribution of external financing. The
findings of these comprehensive and rigorously conducted impact evaluations
should also be made publicly accessible.
Keywords Health financing, donors, developing countries, health outcomes, impact, Africa,
Asia
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KEY MESSAGES
 We found very few studies that adequately demonstrate the full process by which external funding has been translated to
health impact. Most studies do not move beyond statistical association, as opposed to contribution or causation.
 Funding organizations and researchers should increase the emphasis on ensuring data capture along the causal pathway
to demonstrate the effect of external financing.
Introduction
Between 2002 and 2012 global health initiatives, bilateral and
multilateral donor agencies, in particular the Global Fund to
fight AIDS, tuberculosis and malaria (Global Fund), the World
Bank, and the United States President’s Emergency Plan For
AIDS Relief (PEPFAR) and President’s Malaria Initiative (PMI),
together with low- and middle-income countries (LMIC), have
provided considerable resources to enable the scale-up of
disease control programmes for HIV, tuberculosis (TB) and
malaria [Institute for Health Metrics and Evaluation 2011; Katz
et al. 2011; The Global Fund 2011; The United States President’s
Emergency Plan for AIDS Relief (PEPFAR) 2011]. These
investment decisions are generally guided by an ambition to
invest in evidence-based strategies with proven effectiveness.
Yet, to date, few studies have systematically assessed or
synthesized the evidence as to whether these new additional
funds have contributed to health impacts beyond those that
might have been achieved without external assistance: evidence
is needed to demonstrate whether these investments provide
value for money and to guide investment decisions by funding
agencies, particularly in a time where the effectiveness of
development assistance for health is widely being questioned
(Leach-Kemon et al. 2012).
We conducted a systematic review of studies published in the
peer-reviewed and grey literature to assess the extent to which
increased external funding for HIV, malaria and TB control
programmes in LMIC has translated into increased service
coverage and health impact, and analysed these using a causal-
chain framework. Our review spans the period 2003–11,
reflecting the time when such external funding for the three
diseases substantially increased (Institute for Health Metrics
and Evaluation 2011).
Methods
We developed a study protocol, detailing the search strategy,
inclusion criteria, outcomes of interest and analytical methods,
using guidance from the Cochrane Collaboration to generate a
comprehensive and standardized evidence summary. This
protocol was used internally to guide discussions between the
researchers and the Global Fund, which had commissioned the
study, but was not submitted to any trial registers.
Search strategies and screening
Between October 2011 and May 2012, we searched PubMed,
the Cochrane Library, the World Health Organization (WHO)
Global Health Library (regional indexes, WHO Library
Information System), the 3IE Systematic Review Database,
and databases from the World Bank, the Canadian Evaluation
Society, OpenGrey, Kaiser Family Foundation, and the Center
for Global Development. Where possible, we used combinations
of text words and thesaurus terms such as ‘programme
evaluation’ [MeSH], ‘outcome assessment (Health Care)’
[MeSH], ‘financing, organized’ [MeSH], ‘financial support’,
HIV, tuberculosis and malaria. Search strategies were tailored to
the specific databases. For PubMed in particular, we focused on
compiling a comprehensive list of relevant MeSH terms, as
these reduced the need for extensive usage of synonyms to
search titles or abstracts. The search strategy was tested for
robustness by checking whether known articles of relevance
were retrieved this way, and by cross-referencing against
various alternative search terms. A detailed outline of each of
the search strategies used is provided in Annex 1.
Thus identified studies of all designs that provided data on
both an intervention group and a comparison group were
eligible for inclusion. The comparison could be either to a
baseline situation or—preferably—to a concurrent control group
that did not receive the intervention. We placed no restrictions
on eligible units of analysis. Studies were excluded if they were
policy reviews, opinions, editorials, letters to the editor,
commentaries, conference abstracts, or if they did not contain
relevant quantitative data.
Within this set of eligible studies, we considered all studies
reporting effects of external funding for HIV, tuberculosis or
malaria control on (1) intervention coverage, (2) quality and
responsiveness of services, or (3) health outcomes (e.g. morbidity,
mortality, incidence, prevalence). We also looked for outcomes
related to potential harms or adverse effects of external financing.
We considered all external funding for health, regardless of the
amount or the type of health activities supported. It was not
essential for a study to specify the amount of funding, but it
was critical that programme scale-up or introduction of new
activities could be linked to a change in resource availability from
external sources. We excluded studies on programmes that
were funded solely from national resources. We only
considered studies published after 2002 (2003–11), in English
or French language, and excluded all duplicate references.
Two reviewers (TdJ and JH) independently screened all
retrieved titles (k¼ 0.73) and abstracts (k¼ 0.70) to determine
if studies met the inclusion criteria. We retrieved the full text of
all selected articles. The two reviewers then independently
assessed their eligibility for inclusion, with a third author (RB)
acting as an arbiter to resolve disagreements. We also reviewed
references of each article to identify other potentially relevant
titles that were then evaluated the same way.
Data extraction and synthesis
For each study, one of the reviewers (TdJ or JH) extracted the
relevant data to a standardized form. This included data
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regarding the study characteristics (study setting, design, study
period, inclusion and exclusion criteria), external funding
(funding agency, amount, disbursement period), recipients of
the funding (name, type of organization, type and number of
beneficiaries), the activities funded (type, quantity), character-
istics of the baseline and control group, outcomes and potential
confounders. The information was then verified or, if necessary,
revised by the second reviewer (JH or TdJ). Any disagreements
were resolved through discussion. Because of the wide hetero-
geneity in study designs, research questions and outcomes
reported, in addition to reporting on risk of bias based on
methodological quality criteria, we provide a brief qualitative
assessment of each included study, discussing the main
methodological challenges, assumptions and potential sources
of bias (Annex 2).
We present data from the included studies in a summary
table. As we did not consider a meta-analysis of this hetero-
geneous set of studies feasible, to present the results we used a
narrative summary structured around an analytical framework
that uses a causal-chain approach to examine the evidence
along a chain linking financial input, via activities, outputs and
outcomes, to health impacts (Figure 1, top panel). Any
quantitative measures are reported in the same format as in
the original studies.
Quality appraisal
We have assessed the risk of bias in the included studies using
a set of criteria derived from grading systems, such as GRADE,
which focus primarily on data collection and analysis methods
(Atkins et al. 2004). However, since all of the included studies
used non-randomized designs, and most lacked concurrent
controls—relying on historic comparators or regression model-
ling techniques instead—this type of assessment is of limited
value. Therefore, we have additionally assessed the included
studies on criteria such as plausibility, strength and specificity
of association, consistency of findings, and coherence of the
evidence to appraise our findings (Hill 1965; Steketee and
Campbell 2010).
Results
Of the 1657 records retrieved from the searched databases, 210
were retained for further scrutiny. Detailed inspection of their
abstracts produced 46 articles for full text screening (Figure 2).
We initially selected 12 articles for inclusion. The additional 21
titles were retrieved through citation tracking and evaluated to
yield one further article; bringing the total number of included
articles to 13, representing 11 individual studies (Figure 2).
Figure 1 Causal-chain framework, showing the temporal and logical effects of programme investments on health impacts, and the causal-chain
elements for which data were provided in each of the included studies. If an element has been reported, this has been indicated by highlighting the
corresponding segment in the same shade as the element shown in the framework. Elements that were not reported have been left unshaded.
Note: Based on the Global Fund 5-year evaluation study framework (Macro International Inc. 2009)
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Characteristics of the included studies
Each of the 11 included studies described impacts on a single
disease domain: four on HIV, two on tuberculosis and five on
malaria. Nine studies were in Africa (including Kenya, Zambia,
Cameroon, Zanzibar, Malawi) and two in Asia (India, China).
Most studies described country-level programmes, but three
studies (Akachi and Atun 2011; Bendavid and Bhattacharya
2009; Flaxman et al. 2010) analysed findings from across the
African continent. Only the studies by Bendavid and
Bhattacharya (2009) and Jia et al. (2010) used controlled,
albeit non-random, study designs. The others followed various
non-controlled designs or were modelling studies. The studies
reported on a number of different outcome and impact
measures (Tables 1 and 2).
Studies on HIV evaluated scaling up of anti-retroviral treat-
ment (ART) in Kenya (Wools-Kaloustian et al. 2009) and
Malawi (Floyd et al. 2010; Jahn et al. 2008), of prevention
activities in India (Ng et al. 2011), and PEPFAR support for
combined prevention and treatment programmes in 41 coun-
tries (Bendavid and Bhattacharya 2009). In the two included
studies that analysed TB control (Jia et al. 2010; Yumo et al.
2011), external funding was used primarily for strengthening
capacity in diagnosis and treatment of TB in Cameroon
and China, respectively. The impact of external funding for
scaling-up malaria control programmes, centred largely on
distribution of insecticide-treated nets and scale-up of artemi-
sinin-based combination therapy, was assessed in Kenya (Noor
et al. 2007), Zanzibar (Aregawi et al. 2011), and Zambia
(Chizema-Kawesha et al. 2010; Steketee et al. 2008), while
two studies (Akachi and Atun 2011; Flaxman et al. 2010)
compared data from across 44 and 34 African countries,
respectively.
Constructing the causal chain
The included studies varied greatly in the total amount of
external funding involved, ranging from a single grant worth
US$5.8 million (Yumo et al. 2011) to cumulative PEPFAR
spending over 5 years (2003–08) and 12 countries worth US$15
billion (Bendavid and Bhattacharya 2009) (Table 3). Studies
could not be directly compared on the basis of per capita
expenditure, because either the number of beneficiaries of the
intervention was not given or it was not clear how the funds
had been allocated over the project lifetime or the study period.
Three studies assessed individual interventions, namely ART
(Floyd et al. 2010; Jahn et al. 2008; Wools-Kaloustian et al.
2009) or insecticide-treated bed nets (Noor et al. 2007). Seven
others evaluated a more comprehensive package of prevention,
care and treatment activities, sometimes including health
Figure 2 Flow chart showing selection process for included studies
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system strengthening activities such as development of labora-
tories or staff capacity (Akachi and Atun 2011; Aregawi et al.
2011; Bendavid and Bhattacharya 2009; Chizema-Kawesha et al.
2010; Jia et al. 2010; Ng et al. 2011; Steketee et al. 2008; Yumo
et al. 2011). In one study (Flaxman et al. 2010), development
assistance for malaria was not further disaggregated into
specific components. All studies found that the increased
availability of external funds resulted in a degree of programme
scale-up or in the introduction of new activities. However, most
did not provide quantitative data on either the scope of
activities implemented or on the amount of funding involved.
Across the 11 studies, health outcomes and impact were
assessed in a period of less than 1 year to 7 years after the
initial scale-up in funding. It was not possible to characterize
an average time lag from funding to impact more precisely, as
many studies lacked detailed data on funding patterns over
time, and where specified, the funding increase was mostly
gradual and continuing into the period of impact evaluation. It
should also be noted that sometimes the increases in external
funding co-occurred with increases in domestic spending
(Chizema-Kawesha et al. 2010; Jia et al. 2010; Ng et al. 2011;
Steketee et al. 2008) or were additional to other, pre-existing
external funding (Aregawi et al. 2011; Bendavid and
Bhattacharya 2009; Jia et al. 2010).
Eight studies (Akachi and Atun 2011; Chizema-Kawesha et al.
2010; Flaxman et al. 2010; Jahn et al. 2008; Jia et al. 2010; Noor
et al. 2007; Steketee et al. 2008; Wools-Kaloustian et al. 2009;
Yumo et al. 2011) reported the effect of programme scale-up on
service availability and coverage, and subsequently on service
utilization. Programme investments were found to be associated
with increased access and adherence to ART treatment (Wools-
Kaloustian et al. 2009); increased coverage and utilization of
bed nets (Akachi and Atun 2011; Flaxman et al. 2010; Noor
et al. 2007; Steketee et al. 2008); increased coverage of indoor
residual spraying, intermittent preventive therapy in pregnancy,
and artemisinin-combination therapy (Steketee et al. 2008); and
with increased TB case notification and detection (Jia et al.
2010; Yumo et al. 2011) (Table 2).
Health impact was reported in 6 of the 11 studies, which
showed that programme scale-up was associated with reduc-
tions in HIV-related mortality (Bendavid and Bhattacharya
2009; Floyd et al. 2010; Jahn et al. 2008), malaria-related
morbidity and mortality (Akachi and Atun 2011; Aregawi et al.
2011; Chizema-Kawesha et al. 2010; Steketee et al. 2008), lives
saved through ITN/IRS coverage (Akachi and Atun 2011), and
improved TB treatment outcomes (Yumo et al. 2011) (Table 2).
Studies of HIV funding, however, found only limited impact on
the number of new HIV infections Ng et al. (2011) and no
statistically significant effect on adult HIV prevalence or
changes in the number of people living with HIV (Bendavid
and Bhattacharya 2009). Although Ng et al. showed that an HIV
prevention project implemented in six states in India was
associated with reductions in the number of new HIV infections
compared with an estimated counterfactual, there was substan-
tial variation between states in the effect sizes (Ng et al. 2011).
Quality of the studies included
All included studies showed a high risk of bias (Annex 2). As
none of the studies were randomized trials, none used any
method of randomization or concealment of allocation. Only
two studies included a form of control group (Bendavid and
Bhattacharya 2009; Jia et al. 2010); in neither of these was the
control group adequately matched to the intervention group,
although the study by Bendavid and Bjattacharya attempted to
Table 1 Summary of health outcomes and impact measures reported in included studies
Indicator
category
Indicator Studies reporting indicator
Service coverage ART coverage Floyd et al. (2010), Jahn et al. (2008)
TB case detection and notification rates Jia et al. (2010), Yumo et al. (2011)
% of households owning at least one (long lasting)
insecticide treated net
Akachi and Atun (2011), Chizema-Kawesha et al. (2010) and
Steketee et al. (2008), Flaxman et al. (2010), Noor et al. (2007)
% of pregnant women receiving at least two doses of
Intermittent Preventive Therapy
Chizema-Kawesha et al. (2010) and Steketee et al. (2008)
Service utilization % of children under-5 years sleeping under an
insecticide-treated bed net
Noor et al. (2007), Flaxman et al. (2010), Steketee et al. (2008)
ART adherence and loss to follow-up rates Wools-Kaloustian et al. (2009)
Health impacts HIV infections averted Ng et al. (2011)
HIV prevalence Bendavid and Bhattacharya (2009), Ng et al. (2011)
Deaths due to HIV/AIDS Bendavid and Bhattacharya (2009), Floyd et al. (2010)
TB treatment outcomes Yumo et al. (2011)
Malaria cases Aregawi et al. (2011), Chizema-Kawesha et al. (2010)
Anaemia cases Aregawi et al. (2011), Chizema-Kawesha et al. (2010)
Malaria-attributed mortality Akachi and Atun (2011), Aregawi et al. (2011),
Chizema-Kawesha et al. (2010)
All-cause adult mortality Floyd et al. (2010)
All-cause under-5 mortality Chizema-Kawesha et al. (2010)
Lives saved Akachi and Atun (2011)
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a
ct
iv
it
ie
s
K
e
y
fi
n
d
in
g
s
T
B
Ji
a
et
al
.
(2
0
1
0
)
O
b
se
rv
a
ti
o
n
a
l
st
u
d
y,
w
it
h
re
g
re
ss
io
n
m
o
d
el
li
n
g
C
h
in
a
;
3
4
9
2
co
u
n
ti
es
2
0
0
1
–
0
8
G
F
,
W
o
rl
d
B
a
n
k
A
ll
a
sp
ec
ts
o
f
T
B
co
n
tr
o
l
in
c.
T
B
d
ru
g
s,
la
b
st
re
n
g
th
en
in
g
,
tr
a
in
in
g
,
co
m
p
u
te
rs
,
a
n
d
ve
h
ic
le
s)
,
h
ea
lt
h
p
ro
m
o
ti
o
n
m
a
te
ri
a
ls

F
ro
m
2
0
0
2
to
2
0
0
5
ca
se
n
o
ti
fi
ca
ti
o
n
in
cr
ea
se
d
in
a
ll
a
re
a
s,
a
n
d
th
en
st
a
b
il
iz
ed
o
r
b
eg
a
n
to
fa
ll
.
T
h
e
in
cr
ea
se
s
w
er
e
m
u
ch
b
ig
g
er
in
a
re
a
s
su
p
p
o
rt
ed
b
y
th
e
W
o
rl
d
B
a
n
k
(2
3
6
%
)
a
n
d
G
lo
b
a
l
F
u
n
d
(2
2
4
%
)
th
a
n
in
a
re
a
s
th
a
t
o
n
ly
re
ce
iv
ed
C
h
in
es
e
g
o
ve
rn
m
en
t
su
p
p
o
rt
(6
5
%
).

T
h
e
a
ve
ra
g
e
co
st
p
er
T
B
ca
se
n
o
ti
fi
ed
w
a
s
si
m
il
a
r
in
W
o
rl
d
B
a
n
k
,
G
lo
b
a
l
F
u
n
d
,
a
n
d
C
h
in
es
e
g
o
ve
rn
m
en
t
a
re
a
s.
Y
u
m
o
et
al
.
(2
0
1
1
)
C
o
h
o
rt
st
u
d
y,
re
tr
o
sp
ec
ti
ve
C
a
m
er
o
o
n
;
1
d
is
tr
ic
t
h
o
sp
it
a
l
2
0
0
3
–
0
8
G
F
T
ra
in
in
g
in
D
O
T
S
,
la
b
st
re
n
g
th
en
in
g
,
w
a
iv
er
o
f
T
B
tr
ea
tm
en
t
a
n
d
H
IV
te
st
in
g
fe
e
C
o
m
p
a
re
d
w
it
h
P
h
a
se
A
(2
0
0
3
–
0
5
),
a
ft
er
in
tr
o
d
u
ct
io
n
o
f
a
G
lo
b
a
l
F
u
n
d
g
ra
n
t
in
P
h
a
se
B
(2
0
0
6
–
0
8
):

C
a
se
n
o
ti
fi
ca
ti
o
n
(a
ll
T
B
fo
rm
s)
in
cr
ea
se
d
fr
o
m
1
0
2
to
1
9
1
.

C
a
se
d
et
ec
ti
o
n
(n
ew
sm
ea
r-
p
o
si
ti
ve
ca
se
s)
in
cr
ea
se
d
fr
o
m
2
8
.3
%
to
4
1
.6
%
.

T
re
a
tm
en
t
su
cc
es
s
ra
te
(a
ll
fo
rm
s)
in
cr
ea
se
d
fr
o
m
7
5
.3
%
to
8
9
.2
%
.

D
ef
a
u
lt
a
n
d
m
o
rt
a
li
ty
ra
te
s
d
ro
p
p
ed
to
ze
ro
fr
o
m
m
a
x
im
u
m
va
lu
es
(o
ve
r
2
0
0
3
–
0
5
)
o
f
1
5
%
a
n
d
2
3
%
,
re
sp
ec
ti
ve
ly
.
M
a
la
ri
a
A
k
a
ch
i
a
n
d
A
tu
n
(2
0
1
1
)
R
eg
re
ss
io
n
m
o
d
-
el
li
n
g
st
u
d
y
S
u
b
-S
a
h
a
ra
n
A
fr
ic
a
;
3
4
co
u
n
tr
ie
s
2
0
0
2
–
0
8
G
F
,
o
th
er
s
IT
N
s/
L
L
IN
s,
IR
S
A
s
O
ff
ic
ia
l
D
ev
el
o
p
m
en
t
A
ss
is
ta
n
ce
fo
r
m
a
la
ri
a
co
n
tr
o
l
in
cr
ea
se
d
in
th
e
p
er
io
d
2
0
0
2
–
0
8
:

D
is
tr
ib
u
ti
o
n
o
f
IT
N
s
in
cr
ea
se
d
fr
o
m
9
.7
m
il
li
o
n
in
2
0
0
2
to
4
6
m
il
li
o
n
in
2
0
0
8
.

A
ve
ra
g
e
IT
N
/I
R
S
h
o
u
se
h
o
ld
o
w
n
er
sh
ip
in
cr
ea
se
d
fr
o
m
8
.3
%
to
3
3
%
.

C
u
m
u
la
ti
ve
ly
,
th
e
es
ti
m
a
te
d
2
3
7
9
7
1
li
ve
s
(a
m
o
n
g
ch
il
d
re
n
u
n
d
er
5
)
w
er
e
sa
ve
d
d
u
e
to
IT
N
/I
R
S
co
ve
ra
g
e
in
cr
ea
se
.
A
re
g
a
w
i
et
al
.
(2
0
1
1
)
T
im
e
se
ri
es
st
u
d
y
Z
a
n
zi
b
a
r;
6
h
ea
lt
h
fa
ci
li
ti
es
1
9
9
9
–
2
0
0
3
vs
2
0
0
8
G
F
,
P
M
I,
o
th
er
s
A
C
T
,
IT
N
s/
L
L
IN
s,
IR
S
,
IP
T
p
A
ft
er
p
ro
g
ra
m
m
e
sc
a
le
-u
p
:

M
a
la
ri
a
d
ea
th
s
d
ec
re
a
se
d
b
y
9
0
%
,
m
a
la
ri
a
in
-p
a
ti
en
t
ca
se
s
b
y
7
8
%
a
n
d
co
n
fi
rm
ed
m
a
la
ri
a
o
u
t-
p
a
ti
en
t
ca
se
s
b
y
9
9
5%
(a
ll
P
<
0
.0
2
5
).

A
m
o
n
g
ch
il
d
re
n
u
n
d
er
-5
,
a
n
a
em
ia
in
-p
a
ti
en
t
ca
se
s
d
ec
re
a
se
d
b
y
8
5
%
(P
<
0
.0
2
5
);
a
n
a
em
ia
d
ea
th
s
a
n
d
o
u
t-
p
a
ti
en
t
ca
se
s
d
ec
li
n
ed
w
it
h
o
u
t
re
a
ch
in
g
st
a
ti
st
ic
a
l
si
g
n
if
ic
a
n
ce
.

In
ch
il
d
re
n
u
n
d
er
-5
,
th
e
p
ro
p
o
rt
io
n
o
f
a
ll
-c
a
u
se
d
ea
th
s
d
u
e
to
m
a
la
ri
a
fe
ll
fr
o
m
4
6
%
to
1
2
%
(c
o
n
ti
n
u
ed
)
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T
a
b
le
2
C
o
n
ti
n
u
ed
S
tu
d
y
(y
e
a
r)
S
tu
d
y
d
e
si
g
n
S
tu
d
y
se
tt
in
g
E
v
a
lu
a
ti
o
n
p
e
ri
o
d
(s
)
F
u
n
d
in
g
so
u
rc
e
F
u
n
d
e
d
a
ct
iv
it
ie
s
K
e
y
fi
n
d
in
g
s
(P
<
0
.0
1
);
th
o
se
d
u
e
to
a
n
a
em
ia
fr
o
m
2
6
%
to
4
%
(P
<
0
.0
1
).
C
h
iz
em
a
-K
a
w
es
h
a
et
al
.
(2
0
1
0
)
a
n
d
S
te
k
et
ee
et
a
l.
(2
0
0
8
)
C
a
se
st
u
d
y
Z
a
m
b
ia
;
co
u
n
tr
y
2
0
0
0
–
0
8
G
F
,
U
S
A
ID
/P
M
I,
B
M
G
F
,
Ja
p
a
n
In
te
rn
a
ti
o
n
a
l
C
o
o
p
er
a
ti
o
n
A
g
en
cy
a
n
d
o
th
er
s
A
C
T
,
IT
N
s/
L
L
IN
s,
IR
S
,
IP
T
p
,
R
a
p
id
D
ia
g
n
o
st
ic
T
es
ti
n
g

H
o
u
se
h
o
ld
IT
N
o
w
n
er
sh
ip
tr
ip
le
d
b
et
w
ee
n
2
0
0
1
a
n
d
2
0
0
6
,
w
it
h
4
4
%
o
f
h
o
u
se
h
o
ld
s
o
w
n
in
g
a
t
le
a
st
o
n
e
IT
N
in
2
0
0
6
.
IT
N
u
se
d
o
u
b
le
d
b
et
w
ee
n
2
0
0
4
a
n
d
2
0
0
6
,
a
ch
ie
vi
n
g
u
se
le
ve
ls
o
f
2
3
%
in
yo
u
n
g
ch
il
d
re
n
a
n
d
2
4
%
in
p
re
g
n
a
n
t
w
o
m
en
.
A
ft
er
p
ro
g
ra
m
m
e
sc
a
le
-u
p
(2
0
0
6
–
0
8
):

In
cr
ea
si
n
g
IT
N
co
ve
ra
g
e
w
a
s
a
ss
o
ci
a
te
d
in
ti
m
e
a
n
d
lo
ca
ti
o
n
w
it
h
re
d
u
ct
io
n
s
in
p
a
ra
si
ta
em
ia
(5
3
%
)
a
n
d
se
ve
re
a
n
a
em
ia
(6
8
%
)
in
ch
il
d
re
n
u
n
d
er
-5
.

6
2
%
o
f
p
re
g
n
a
n
t
w
o
m
en
re
ce
iv
ed
a
t
le
a
st
tw
o
d
o
se
s
o
f
IP
T
p
vs
5
4
%
b
ef
o
re
sc
a
le
-u
p
.

U
n
d
er
-5
m
o
rt
a
li
ty
fe
ll
fr
o
m
1
6
8
to
1
1
9
p
er
1
0
0
0
li
ve
b
ir
th
s.
F
la
x
m
a
n
et
al
.
(2
0
1
0
)
R
eg
re
ss
io
n
m
o
d
el
li
n
g
st
u
d
y
A
fr
ic
a
;
4
4
co
u
n
tr
ie
s
1
9
9
9
–
2
0
0
8
A
ll
ex
te
rn
a
l
fu
n
d
in
g
fo
r
m
a
la
ri
a
IT
N
s
E
x
cl
u
d
in
g
fo
u
r
o
u
tl
ie
r
co
u
n
tr
ie
s,
ea
ch
U
S
$
1
p
er
ca
p
it
a
in
m
a
la
ri
a
d
ev
el
o
p
m
en
t
a
ss
is
ta
n
ce
fo
r
h
ea
lt
h
w
a
s
a
ss
o
-
ci
a
te
d
w
it
h
a
n
in
cr
ea
se
in
IT
N
h
o
u
se
h
o
ld
o
w
n
er
sh
ip
co
ve
ra
g
e
(5
.3
%
p
o
in
ts
)
a
n
d
IT
N
u
se
in
ch
il
d
re
n
u
n
d
er
-5
(4
.6
%
p
o
in
ts
).
N
o
o
r
et
al
.
(2
0
0
7
)
C
o
h
o
rt
st
u
d
y,
p
ro
sp
ec
ti
ve
K
en
ya
;
4
d
is
tr
ic
ts
2
0
0
4
–
0
6
G
F
,
D
F
ID
IT
N
s/
L
L
IN
s

T
h
e
p
ro
p
o
rt
io
n
o
f
ch
il
d
re
n
u
n
d
er
-5
w
h
o
sl
ep
t
u
n
d
er
a
re
ce
n
tl
y
tr
ea
te
d
IT
N
in
th
e
p
re
vi
o
u
s
n
ig
h
t
in
cr
ea
se
d
fr
o
m
7
.1
%
in
2
0
0
4
,
to
2
3
.5
%
in
2
0
0
5
(a
ft
er
in
tr
o
d
u
c-
ti
o
n
o
f
h
ea
vi
ly
su
b
si
d
iz
ed
n
et
s)
,
a
n
d
to
6
7
.3
%
in
2
0
0
6
(a
ft
er
in
tr
o
d
u
ct
io
n
o
f
fr
ee
m
a
ss
d
is
tr
ib
u
te
d
IT
N
s)
.

S
o
ci
o
ec
o
n
o
m
ic
in
eq
u
it
y
in
n
et
co
ve
ra
g
e
p
ro
g
re
ss
iv
el
y
d
ec
re
a
se
d
.
N
ot
e:
A
C
T
¼
a
rt
em
is
in
in
-b
a
se
d
co
m
b
in
a
ti
o
n
th
er
a
p
y;
A
R
T
¼
a
n
ti
-r
et
ro
vi
ra
l
th
er
a
p
y;
IP
T
p
¼
in
te
rm
it
te
n
t
p
re
ve
n
ti
ve
th
er
a
p
y
in
p
re
g
n
a
n
cy
;
IR
S
¼
in
d
o
o
r
re
si
d
u
a
l
sp
ra
yi
n
g
;
IT
N
¼
in
se
ct
ic
id
e-
tr
ea
te
d
n
et
;
L
L
IN
¼
lo
n
g
-
la
st
in
g
in
se
ct
ic
id
a
l
n
et
;
P
L
H
IV
¼
p
er
so
n
li
vi
n
g
w
it
h
H
IV
.
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T
a
b
le
3
S
u
m
m
a
ry
o
f
fu
n
d
in
g
d
a
ta
re
p
o
rt
ed
in
in
cl
u
d
ed
st
u
d
ie
s
S
tu
d
y
E
x
te
rn
a
l
fu
n
d
in
g
O
th
e
r
fu
n
d
in
g
F
u
n
d
in
g
p
e
ri
o
d
b
S
o
u
rc
e(
s)
A
m
o
u
n
ta
S
o
u
rc
e(
s)
A
m
o
u
n
t
H
IV
B
en
d
a
vi
d
a
n
d
B
h
a
tt
a
ch
a
ry
a
(2
0
0
9
)
P
E
P
F
A
R
U
S
$
1
5
b
(U
S
$
6
b
il
li
o
n
d
is
b
u
rs
ed
b
y
2
0
0
7
)
G
o
ve
rn
m
en
ts
,
G
F
a
n
d
o
th
er
d
o
n
o
rs
N
o
t
sp
ec
if
ie
d
2
0
0
3
–
0
8
F
lo
yd
et
al
.
(2
0
1
0
)
a
n
d
Ja
h
n
et
al
.
(2
0
0
8
)
G
F
N
o
t
sp
ec
if
ie
d
N
o
t
sp
ec
if
ie
d
2
0
0
4
–
?
N
g
et
al
.
(2
0
1
1
)
B
il
l
a
n
d
M
el
in
d
a
G
a
te
s
F
o
u
n
d
a
ti
o
n
U
S
$
2
5
8
m
G
o
ve
rn
m
en
t
U
S
$
4
6
0
m
il
li
o
n
fo
r
p
h
a
se
2
(1
9
9
9
–
2
0
0
6
);
U
S
$
2
.5
b
fo
r
p
h
a
se
3
(2
0
0
7
–
1
2
),
o
f
w
h
ic
h
tw
o
-t
h
ir
d
s
a
ll
o
ca
te
d
fo
r
H
IV
p
re
ve
n
ti
o
n
.
2
0
0
3
–
0
8
W
o
o
ls
-K
a
lo
u
st
ia
n
et
al
.
(2
0
0
9
)
P
E
P
F
A
R
U
S
$
6
.5
m
þ
fr
ee
A
R
V
s
N
o
t
sp
ec
if
ie
d
2
0
0
4
–
?
T
B
Ji
a
et
al
.
(2
0
1
0
)
G
F
,
W
B
,
o
th
er
s
W
B
þ
o
th
er
s
U
S
$
4
3
2
m
;
G
F
U
S
$
1
5
1
m
c
C
en
tr
a
l
a
n
d
lo
ca
l
g
o
ve
rn
m
en
t
U
S
$
1
5
9
m
2
0
0
1
–
0
8
Y
u
m
o
et
al
.
(2
0
1
1
)
G
F
U
S
$
5
.8
m
G
o
ve
rn
m
en
t
N
o
t
sp
ec
if
ie
d
2
0
0
5
–
0
9
M
a
la
ri
a
A
k
a
ch
i
a
n
d
A
tu
n
(2
0
1
1
)
A
ll
d
ev
el
o
p
m
en
t
a
ss
is
ta
n
ce
fo
r
m
a
la
ri
a
co
n
tr
o
l,
in
cl
u
d
in
g
G
F
U
S
$
1
.9
b
,
o
f
w
h
ic
h
G
F
U
S
$
1
.4
b
(a
s
d
is
b
u
rs
ed
b
y
2
0
0
8
)
N
o
t
sp
ec
if
ie
d
2
0
0
2
–
0
8
A
re
g
a
w
i
et
al
.
(2
0
1
1
)
G
F
,
P
M
I,
o
th
er
s
N
o
t
sp
ec
if
ie
d
G
o
ve
rn
m
en
t
N
o
t
sp
ec
if
ie
d
2
0
0
3
–
?
C
h
iz
em
a
-K
a
w
es
h
a
et
al
.
(2
0
1
0
)
a
n
d
S
te
k
et
ee
et
al
.
(2
0
0
8
)
G
F
,
U
S
A
ID
/P
M
I,
W
B
,
a
n
d
o
th
er
s
U
S
$
1
3
0
m
G
o
ve
rn
m
en
t
N
o
t
sp
ec
if
ie
d
2
0
0
3
–
0
8
F
la
x
m
a
n
et
al
.
(2
0
1
0
)
A
ll
d
ev
el
o
p
m
en
t
a
ss
is
ta
n
ce
fo
r
m
a
la
ri
a
co
n
tr
o
l
N
o
t
sp
ec
if
ie
d
N
o
t
sp
ec
if
ie
d
2
0
0
0
–
0
8
N
o
o
r
et
al
.
(2
0
0
7
)
D
F
ID
,
G
F
U
S
$
1
0
6
m
(D
F
ID
U
S
$
5
6
m
;
G
F
U
S
$
1
7
m
)
N
o
t
sp
ec
if
ie
d
2
0
0
4
–
?
N
ot
es
:
a
T
h
e
a
m
o
u
n
ts
re
p
o
rt
ed
a
re
th
o
se
th
a
t
w
er
e
al
lo
ca
te
d
in
th
e
fo
rm
o
f
g
ra
n
ts
o
r
d
o
n
o
r
p
le
d
g
es
,
u
n
le
ss
sp
ec
if
ie
d
o
th
er
w
is
e.
A
R
V
¼
a
n
ti
re
tr
o
vi
ra
ls
;
G
F
¼
T
h
e
G
lo
b
a
l
F
u
n
d
to
F
ig
h
t
A
ID
S
,
T
u
b
er
cu
lo
si
s
a
n
d
M
a
la
ri
a
;
P
M
I
¼
T
h
e
P
re
si
d
en
t’
s
M
a
la
ri
a
In
it
ia
ti
ve
;
U
S
A
ID
¼
T
h
e
U
n
it
ed
S
ta
te
s
A
g
en
cy
fo
r
In
te
rn
a
ti
o
n
a
l
D
ev
el
o
p
m
en
t;
W
B
¼
T
h
e
W
o
rl
d
B
a
n
k
.
b
T
h
e
fu
n
d
in
g
p
er
io
d
re
fe
rs
p
ri
n
ci
p
a
ll
y
to
th
e
p
er
io
d
o
ve
r
w
h
ic
h
th
e
ex
te
rn
al
fu
n
d
in
g
w
a
s
p
ro
vi
d
ed
.
If
th
e
fu
n
d
in
g
p
er
io
d
o
ve
r
w
h
ic
h
st
a
te
d
o
th
er
fu
n
d
in
g
w
a
s
p
ro
vi
d
ed
d
if
fe
rs
,
th
is
h
a
s
b
ee
n
in
d
ic
a
te
d
se
p
a
ra
te
ly
.
If
th
e
in
cl
u
d
ed
st
u
d
y
o
n
ly
m
en
ti
o
n
ed
a
st
a
rt
in
g
ye
a
r
fo
r
th
e
fu
n
d
in
g
,
w
it
h
o
u
t
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correct for differences in baseline characteristics during ana-
lysis. In none of the studies that used controls, it was
clear whether blinding of outcome assessors or analysts took
place. It was not possible to judge whether any selective
outcome reporting took place, as we did not retrieve any study
protocols.
A number of additional quality issues were evident in the
studies included in the review. The first of these relates to
incomplete or weak data sets used by the studies, as explicitly
acknowledged by some study authors, which meant study
findings had to be interpreted with caution (Aregawi et al. 2011;
Chizema-Kawesha et al. 2010; Jia et al. 2010). In order to, at
least partially, overcome the problem of weak data sets, two of
the studies strengthened the evidence for impact of malaria
control activities on malaria-attributed morbidity and mortality
by providing corroborating data on associated parameters such
as parasitaemia and anaemia prevalence (Aregawi et al. 2011;
Chizema-Kawesha et al. 2010; Steketee et al. 2008).
The second issue relates to attribution of observed impacts to the
intervention according to our framework. Although the causal-
chain framework outlines a logical path from investments to
outcomes and impact, this may be an over-simplification in cases
where there is progressive implementation of a package of
activities. For instance, in two of the included studies (Aregawi
et al. 2011; Chizema-Kawesha et al. 2010) the malaria disease
burden was already declining before programmes had been
implemented in their entirety—declines attributed to one or
more elements introduced before the remainder of the package. In
some studies the time between the intervention and the assess-
ment may have been too short to observe health impacts, but
reported improvements in intermediate output and outcome
indicators have helped build a case for plausible contribution of
investments to improved impacts. A particular challenge is that
most of the included studies were not experimental designs with
proper controls. Thus, it is difficult to rule out that the observed
effects would not have occurred without the external invest-
ments. Three of the included studies (Akachi and Atun 2011;
Aregawi et al. 2011; Ng et al. 2011) attempted to tackle this design
problem by comparing findings against hypothetical ‘counterfac-
tuals’ obtained through modelling. The validity of these
approaches, however, rests on the quality of the data, robustness
of the models employed, the suitability of the counterfactual used
and the accuracy of the input variables, all of which are difficult to
independently corroborate.
Third, a valuable indication of the validity of the overall
evidence relates to the strength of association between the
intervention and the observed effect size. Particularly in the
HIV studies, some of the observed effects were relatively small,
whilst other effects were not statistically significant (Bendavid
and Bhattacharya 2009; Floyd et al. 2010; Jahn et al. 2008; Ng
et al. 2011). The strength of the evidence for a causal impact of
the programme interventions is strongest when there is a
demonstrable ‘dose–effect’ relationship between the intensity of
services and the observed impacts. Three studies indeed
observed an association between the amount of investment
and the magnitude of impact on HIV prevalence (Ng et al.
2011), the number of lives saved due to ITN/IRS coverage
(Akachi and Atun 2011), or the number of TB cases reported
(Jia et al. 2010), respectively.
Discussion
Whilst the included studies are heterogeneous in the types and
magnitudes of the reported effects, settings and sample sizes,
their findings consistently point to improved health outcomes
and impacts. The combined evidence across all included studies
therefore suggests that in the period studied external funding
for HIV, TB and malaria control has contributed to reductions
in morbidity and mortality from these three major diseases.
However, this evidence is derived from only a small set of
studies that were identified in the peer-reviewed literature and
it is thus difficult to draw conclusions about impacts more
generally. Furthermore, only two of the included studies
(Akachi and Atun 2011; Floyd et al. 2010; Jahn et al. 2008)
provided evidence on the entire casual chain—from invest-
ments to activities, outputs, outcomes and impact—and were
hence able to directly link impact to external funding. All
others fell short of reporting to what extent activities were
scaled up, what outputs were generated, or what outcomes
were achieved as a result of financing, and could thus only
show statistical association. This paucity of scientifically rigor-
ous, published studies to generate evidence is remarkable,
considering the US$ 202 billion spent over the period 2002–11
on Development Assistance for Health (Institute for Health
Metrics and Evaluation 2011).
Whilst this review finds that in several of the 11 included
studies, overall external funding in HIV, TB and malaria
programmes was associated with improved health impact,
with contribution demonstrated in some, questions about the
sustainability of these health impacts remain unanswered. One
study included in the review (Jia et al. 2010) showed how with
reduced external funding programme efforts diminished, re-
sulting in a worsening of health outcomes. Others have argued
that continued funding is needed to sustain or exceed current
levels of impact, albeit without underpinning evidence to
support such arguments (Noor et al. 2007; Wools-Kaloustian
et al. 2009). Although these claims seem convincing at face
value, as yet, they lack a strong empirical basis.
The studies included in the review provide limited evidence of
whether external funding has increased accessibility to services,
particularly for underprivileged and vulnerable groups. Only
four studies explored the equity dimension of investments, with
three (Chizema-Kawesha et al. 2010; Jia et al. 2010; Noor et al.
2007) showing positive benefits of overcoming inequitable
service provision. This potential for global health initiatives to
produce greater equity in access to health services has been
noted previously (Hanefeld 2008), but further assessment is
required to demonstrate realization of this potential.
It is worth noting that none of the included studies reported
on adverse effects from the external funding nor was the
potential for such effects discussed beyond the aforementioned
concerns regarding programme sustainability. Known examples
of adverse effects include health worker migration from other
programmes into the externally funded programmes, or dimin-
ished focus on other health services leading to a worsening of
health outcomes in these areas.
Limitations of this review
Our conclusions are based on only 11 studies, which are
unlikely to be representative of all externally funded
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programmes in over 150 countries (The Global Fund 2012) for
several reasons. First, for the objective of this review it was
essential that studies explicitly reported the role of external
funding in programme scale-up so that any observed impacts
could be linked to changes in external funding. Consequently,
studies that did not explicitly describe underlying funding
changes or did not link funding changes to health outcomes
had to be excluded, even if external funding was likely or
known to have enabled the documented programme scale-up.
For example, programme scale-up in impact assessments by
Otten et al. (2009) and Reniers et al. (2009) was likely enabled
by external funds, but this was not made explicit and so we
excluded these studies. Likewise, whilst studies by Sharp et al.
(2007) and by Steketee and Campbell (2010) did refer to
increased external funding, outcome measures were not tem-
porally linked to these funding changes so that it was not
possible to determine impact from this funding. Second, whilst
we have aimed to identify all relevant studies, our search
methodology presents some limitations. As in any systematic
search, we may have missed relevant studies if search terms
were not present in the MeSH terms, title or abstract of the
article. Moreover, we could not take into account the large
number of evaluations, country reviews and management
reports that are used by programmes or national governments
themselves, since most of these are not available or indexed in
searchable, open-access databases. Contacting the major fund-
ing agencies directly to request this documentation was
discussed, but ultimately not pursued because of the unsys-
tematic nature of such a strategy, which could have introduced
additional sources of bias. These concerns are amplified by the
fact that the evaluation literature is likely to show a publication
bias towards successful interventions (Dwan et al. 2008; Song
et al. 2009). Particularly when studies are directly commissioned
or funded by organizations with a vested interest, for instance
to advocate for continued contributions from donors, caution
should be exercised when interpreting the evidence base. Third,
some of the 11 studies included present findings from small-
scale projects with no more than a few hundred beneficiaries
and relatively small amounts of external funding, and as such
may not present an accurate reflection of the true scope of all
externally funded programmes.
An additional consideration in interpreting the evidence from
this review is that we have taken a rather simplistic, linear view
of the causal chain between external investments and impacts.
In reality, this pathway may be affected by a multitude of
contextual factors that can act to either enforce or counter the
direction of effect. Yet, most of the included studies are short
on the contextual details that can influence programme
effectiveness, such as the social acceptability of interventions
or the characteristics of the health system in which supported
programmes are set (Atun et al. 2005; Katz et al. 2010;
Tkatchenko-Schmidt et al. 2010). At worst, it is possible for
external funding to produce undesirable side effects (Car et al.
2012). For example, this review has not looked at the impact
external funding has had on domestic health spending. Whilst
external contributions are generally contingent upon addition-
ality, it is conceivable governments’ budget allocation decisions
are informed by the anticipated availability of other funds.
Consequently, increases in external funding may lead to
displacement of government funds, eventually resulting in
reduced programme ownership and sustainability (Farag et al.
2009; Lu et al. 2010). Also impacts of external funding on,
among others, governance, health sector efficiency or health
worker migration patterns fall beyond the scope of this review,
although these are important considerations in policy discus-
sions concerning development assistance for health.
Implications for policy and research
The narrow base on which the conclusions of this review are
founded should not be interpreted to mean that external funds
from donors and global health initiatives have had little impact,
or that data on positive health benefits of these investments do
not exist. What this review highlights, however, is a shortage of
studies that are conducted to a rigorous scientific standard, and
of which results are made publicly available, to generate much
needed evidence on health impact, effectiveness and efficiency
of external funding. Even fewer such studies have adequately
provided information on all steps along the causal chain. In
fact, this lack of comprehensive, robust and reliable data has
also been recognized by others as a major problem in the debate
on aid effectiveness (Stuckler et al. 2012). We recommend wider
use of this framework in developing and publishing impact
studies, with an emphasis on demonstrating attribution. These
studies should include an adequate description of contextual
factors impacting at all stages along the causal chain, and be
inclusive of reporting potential undesirable effects. This requires
a more systemic approach to impact evaluation than one that is
focused solely on programme outcomes—ideally also account-
ing for system-wide effects.
One would expect that as a result of substantial investments
in data collection systems for health programmes made over the
last decade by major financing institutions, a wealth of
rigorously conducted studies would have been published,
covering the full sequence from financing, through inputs,
outputs and outcomes, to health impact (Shakarishvili et al.
2010; The Global Fund 2011). Indeed, in recent years countries
and key international financing agencies have been making
strides in evaluating their achievements. Between 2006 and
2010, global health initiatives have launched several evaluation
strategies and agendas [President’s Malaria Initiative 2012; The
Global Fund to Fight AIDS Tuberculosis and Malaria 2012; The
United States President’s Emergency Plan for AIDS Relief
(PEPFAR) 2012], and technical agencies have produced guide-
lines for standardized national programme reviews and evalu-
ations (UNAIDS 2012; World Health Organization 2009, 2010).
Increasing numbers of donor-supported national HIV, TB and
malaria programmes are conducting comprehensive programme
reviews and evaluations, supported by activities to strengthen
essential data collection through routine disease surveillance
systems, surveys, data quality assessments and sometimes
sentinel sites. However, it has been noted previously that
routine evaluation frameworks and policies are frequently not
clearly articulated up front; rather, decisions on what to
evaluate, and when, are often made ad hoc and evaluation
requirements vary between funding organizations (Kebede et al.
2012).
Furthermore, evaluations conducted, or commissioned, by
funding agencies vary in the strength of their design and the
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quality of data and analysis, and are rarely put through a
process of scientific peer-review and publication. In itself this is
not surprising as this process is generally time-consuming and
labour intensive, at odds with the consultancy-driven nature of
many programme evaluations, which are conducted to tight
deadlines and are aimed primarily at providing rapid, actionable
recommendations. There is, in truth, very little incentive for
funding agencies to engage in peer-reviewed publishing, which
is mainly the domain of academic researchers.
Overall, our findings suggest a need for increased investment
in strong country-level comprehensive evaluations, the results
of which are to be made publicly accessible and preferably
subject to peer-review. First, funding agencies should work to
improve reporting of their funding in a standardized and
transparent manner, with proper documentation of programme
spending by source and service delivery area (Sridhar and
Batniji 2008). Furthermore, investments aimed at strengthening
country level health information systems should ensure data
capture along the full causal pathway to demonstrate effect and
contribution of external financing. In these challenging eco-
nomic times, there is a clear case for donors and countries to
support publicly accessible, rigorous and comprehensive pro-
gramme impact evaluations to demonstrate value for money.
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